Hypoplastic myelodysplastic syndrome (h-MDS) is a distinctive clinical entity with poorer prognosis and frequent karyotypic and FISH abnormalities compared to aplastic anemia (AA)-Reference-Cited by-同舟云学术

Hypoplastic myelodysplastic syndrome (h-MDS) is a distinctive clinical entity with poorer prognosis and frequent karyotypic and FISH abnormalities compared to aplastic anemia (AA)

Published:2010-10 Issue:10 Volume:34 Page:1344-1350
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Koh Youngil,Lee Hye Ryun,Song Eun Young,Kim Hyun Kyoung,Kim Inho,Park Seonyang,Park Myoung Hee,Kim Byoung Kook,Yoon Sung-Soo,Lee Dong Soon

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference26 articles.

1. Hypoplastic myelodysplastic syndrome—a clinical, morphologic, or genetic diagnosis?;Wong;Cancer Genet Cytogenet,2002

2. Hypoplastic myelodysplastic syndrome: Incidence, morphology, cytogenetics, and prognosis;Maschek;Ann Hematol,1993

3. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by international prognostic scoring system, cytogenetic and genetic studies;Huang;Leukemia,2008

4. Hypocellularity in myelodysplastic syndrome is an independent factor, which predicts a favorable outcome;Yue;Leuk Res,2008

5. Acquired aplastic anemia;Young;Ann Intern Med,2002

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lung transplant recipients with telomere-mediated pulmonary fibrosis have increased risk for hematologic complications;American Journal of Transplantation;2023-10

2. Myelodysplastic syndrome: Approach to diagnosis in the era of personalized medicine;Seminars in Diagnostic Pathology;2023-05

3. Circulating HMGB1 is increased in myelodysplastic syndrome but not in other bone marrow failure syndromes: proof-of-concept cross-sectional study;THER ADV HEMATOL;2022

4. Circulating HMGB1 is increased in myelodysplastic syndrome but not in other bone marrow failure syndromes: proof-of-concept cross-sectional study;Therapeutic Advances in Hematology;2022-01

5. Hypoplastic myelodysplastic syndrome and acquired aplastic anemia: Immune‑mediated bone marrow failure syndromes (Review);International Journal of Oncology;2021-12-23